Benoit Tessoulin
Overview
Explore the profile of Benoit Tessoulin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwiatek M, Guru Murthy G, Hoffmann M, Tessoulin B, Danilov A, Alencar A, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 40000354
Background: LOXO-338 is a novel, orally bioavailable small-molecule inhibitor of Bcl-2, designed to achieve selectivity for Bcl-2 over Bcl-xL, thus avoiding dose-limiting thrombocytopenia associated with Bcl-xL inhibition. This first-in-human, open-label,...
2.
Harrison S, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al.
N Engl J Med
. 2025 Feb;
392(7):677-685.
PMID: 39938094
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cilta-cel) in the phase 3 CARTITUDE-4 trial....
3.
Marouf A, Chaubard S, Lievin R, Michot J, Molinari N, Rossignol J, et al.
Hemasphere
. 2025 Jan;
9(1):e70081.
PMID: 39840381
No abstract available.
4.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, et al.
Blood Adv
. 2024 Aug;
8(20):5371-5381.
PMID: 39163620
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with...
5.
Reizine F, Issa N, Lecuyer R, Tessoulin B, Gaborit B
Intensive Care Med
. 2024 Aug;
50(10):1719-1720.
PMID: 39102026
No abstract available.
6.
Gaborit B, Lecuyer R, Issa N, Camou F, Lavergne R, Gabriel F, et al.
Chest
. 2024 Jun;
166(4):708-711.
PMID: 38866071
No abstract available.
7.
Sarkozy C, Callanan M, Thieblemont C, Oberic L, Burroni B, Bouabdallah K, et al.
Blood
. 2024 Apr;
144(3):262-271.
PMID: 38669626
Obinutuzumab (O) and rituximab (R) are 2 CD antibodies that have never been compared in a prospective randomized trial of mantle cell lymphoma (MCL). Herein, we report the long-term outcome...
8.
Antier C, Jullien M, Tessoulin B, Loirat M, Peterlin P, Garnier A, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611097
Late relapse, beyond 2 years following alloHSCT for AML, is rare. Among the 376 patients allografted for AML in our center between 1990 and 2016, 142 (38%) relapsed. The majority...
9.
Sarkozy C, Tessoulin B, Chiron D
Blood
. 2024 Mar;
145(7):696-707.
PMID: 38551811
Mantle cell lymphoma (MCL) is a rare (5%-7%), aggressive B-cell non-Hodgkin lymphoma with well-defined hallmarks (eg, cyclin D1, SOX11), and its expansion is highly dependent on the tumor microenvironment (TME)....
10.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, et al.
Haematologica
. 2024 Mar;
109(7):2297-2302.
PMID: 38497158
No abstract available.